Therefore, to address this aspect, the work conducted herein evaluated the in vitro antitumor activities of both QUE and 5-FU, applied as individual and combinatorial treatments, using the A375 human melanoma cell line as an experimental model for CM, considering that these cells present the BRAF V600E mutation detected in approximately 50% of all CM patients [37,38]. The gene discussed is BRAF; the disease is cutaneous mastocytosis.